Table 3.

Study measurements by visit^a

Area	Measurement	Follow-Up Month
		0	3 to 6	12	24	36	48
General	Physical examination/medical history	X	X	X	X	X	X
	Medication use	X	X	X	X	X	X
	Symptoms checklist	X	X	X	X	X	X
Kidney	Iohexol-based GFR	X		X		X
	Central renal panel	X		X	X	X	X
	Central urine creatinine, proteinb	X		X	X	X	X
	Cystatin C–based GFR	X		X		X
	HPLC serum creatinine	X		X	X	X	X
	Local basic metabolic panel	X		X	X	X	X
	Local urine creatinine, proteinb	X		X	X	X	X
	Local complete blood count	X		X	X	X	X
	Local pregnancy test	X		X	X	X	X
Cardiovascular	Echocardiography			X		X
	ABPM			X		X
	Carotid IMTc (n = 30)			X		X
	Lipid profile			X		X
	Clinical BP	X	X	X	X	X	X
Neurocognitive	Pediatric quality of life		X	X	X	X	X
	Cognitive and development		X		X		X
	Behavioral assessment		X		X		X
	Magnetic resonance imaged (n = 30)		X		X		X
	Neuropsychological assessmentsd (n = 30)		X		X		X
Growth and nutrition	Height or length	X	X	X	X	X	X
	Weight	X	X	X	X	X	X
	Head and mid-arm circumference	X	X	X	X	X	X
	Tanner stage	X	X	X	X	X	X
	3-d diet record, food frequency		X	X	X	X	X
	Physical activity		X	X	X	X	X
Inflammation	Wide-range C-reactive protein		X		X
Bone health	Intact PTH		X		X		X
	Bone biopsyc (n = 10)		X		X

^aABPM, ambulatory BP monitoring; IMT, intima-media thickness; PTH, parathyroid hormone.

^bFirst morning urine specimen collection.

^cSubcohort studies for carotid IMT and bone biopsy at select sites with technical capability to perform the specific tests.

^dHigh-risk neurocognitive testing and imaging will be performed at three sites with specific imaging capabilities in children who are older than 9 yr and have GFR <40 ml/min per 1.73 m². High-risk neurocognitive assessment includes Children’s Memory Scale (CMS), Delis-Kaplan Executive Function System (D-KEFS), Benton Judgment of Line Orientation and Form Discrimination (Benton), and Clinical Evaluation of Language Fundamentals, Fourth Edition (CELF-4).